Collagen gel droplet-embedded culture drug sensitivity test for adjuvant chemotherapy after complete resection of non-small-cell lung cancer.

Autor: Inoue, Masayoshi, Maeda, Hajime, Takeuchi, Yukiyasu, Fukuhara, Kenjiro, Shintani, Yasushi, Funakoshi, Yasunobu, Funaki, Soichiro, Nojiri, Takashi, Kusu, Takashi, Kusumoto, Hidenori, Kimura, Toru, Okumura, Meinoshin, Representing the Thoracic Surgery Study Group of Osaka University
Předmět:
Zdroj: Surgery Today; Apr2018, Vol. 48 Issue 4, p380-387, 8p
Abstrakt: Purpose: We conducted a prospective clinical study to individualize adjuvant chemotherapy after complete resection of non-small-cell lung cancer (NSCLC), based on the drug sensitivity test.Methods: Patients with resectable c-stage IB-IIIA NSCLC were registered between 2005 and 2010. We performed the collagen gel droplet-embedded culture drug sensitivity test (CD-DST) on a fresh surgical specimen to assess in vitro chemosensitivity and evaluated the prognostic outcome after adjuvant chemotherapy with carboplatin/paclitaxel based on the CD-DST.Results: Among 92 registered patients, 87 were eligible for inclusion in the analysis. The success rate of CD-DST was 86% and chemosensitivity to carboplatin and/or paclitaxel was evident in 57 (76%) of the 75 patients. Adjuvant chemotherapy was completed in 22 (73%) of 30 patients. The 5-year overall survival rates were 71, 73, and 75% for all, CD-DST success, and chemosensitive patients, respectively. The 5-year disease-free survival and overall survival rates of the chemosensitive patients who completed adjuvant chemotherapy using carboplatin/paclitaxel were 68 and 82%, respectively. The 5-year disease-free survival and overall survival rates of the patients with stage II-IIIA chemosensitive NSCLC were 58 and 75%, respectively. Comparative analyses of the chemosensitive and non-chemosensitive/CD-DST failure groups showed no significant survival difference.Conclusions: CD-DST can be used to evaluate chemosensitivity after lung cancer surgery; however, its clinical efficacy for assessing individualized treatment remains uncertain. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: